NCT04713176 - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

May 2, 2022

Study Completion Date

December 9, 2022

Conditions

Severe COVID-19

Interventions

DRUG

DWJ1248 with Remdesivir

1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV

DRUG

Placebo with Remdesivir

1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV

Trial Locations (1)

National Medical Center, Seoul